<DOC>
	<DOCNO>NCT00466284</DOCNO>
	<brief_summary>A open label non- randomized Phase II trial . It anticipate approximately 46 patient treat . STUDY OBJECTIVES Primary : Objective response rate Secondary : Progression free survival , Overall survival Safety Tarceva</brief_summary>
	<brief_title>Phase II Trial Tarceva Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Study Design : Phase II trial , open label , non-randomized multicenter . Expected total enrollment : 46 Study start : January , 2006 Study completation : January , 2008</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Age 18 year . Patients must histologically confirm diagnosis nonsmall cell lung cancer , surgically resectable ( stage IA IIIB ) . Measurable disease . Written informed consent must obtain prior inclusion trial . Karnofsky performance status 80 % . Patients must treat prior chemotherapy radioterapy . Patients must adequate bone marrow , liver renal function . Bone Marrow : WBC &gt; 3000 x 103/mm3 , Platelets &gt; 100 x 103/mm3 , Hgb &gt; 10.0 gm/dl , ANC &gt; 1500 x 103/mm3 , Hepatic : Bilirubin &lt; 2 mg/dl ( 34 µmol/l ) ; AST , ALT , Alkaline Phosphatase &lt; 5 x normal , Renal : Creatinine &lt; 1.5 mg/dl ( 132 µmol/l ) . Female patient pregnant lactate . Patients use investigational agent within 21 day prior study entry . Patients receive prior treatment erlotinib antiEGFR agent . Significant comorbidity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>